Skip to main content
Premium Trial:

Request an Annual Quote

Biocept Nabs BCBS Texas In-Network Provider Agreement

NEW YORK (GenomeWeb) – Biocept said today that it has secured an in-network provider agreement with Blue Cross Blue Shield of Texas, the largest provider of health benefits in that state.

The agreement raises the number of patients with in-network access to Biocept's liquid biopsy tests to about 185 million, with some members having access via multiple plans, the company said. Biocept has steadily increased its menu of assays over the last year and currently offers tests for alterations in a variety of cancer-associated genes in both circulating tumor cells and circulating cell-free DNA.

"It is gratifying that health plans are seeing the value of our liquid biopsy approach for profiling and monitoring important cancer biomarkers," Biocept President and CEO Michael Nall said in a statement. "Partnering with health insurers is a major focus of our business strategy, as it may increase physician access to this non-invasive technology for their patients and provide timely adjudication of claims for patients.

He added that the agreement is an especially important one for Biocept as Texas is one of the firm's largest markets.

Biocept also announced a similar agreement with Blue Cross Blue Shield of Illinois last year, and has previously signed coverage agreements with a variety of preferred provider networks.



The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.